insight weekly alert

Vol. 106, 2026 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

1. Summary of the Week

From November 14 to 20, a total of 25 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 6 were China-related, defined as transactions involving at least one China-based company. These comprised five out-licensing deals and one domestic partnership.

In China, the largest transaction involved Starna Therapeutics and Pfizer for the three preclinical investigational in vivo CAR-T programs targeting autoimmune diseases, with an upfront payment of $330 million and a total deal value of $2.6 billion.

Outside China, 19 deals were announced. The largest transaction involved a strategic collaboration between DISCO Pharmaceuticals and AbbVie to advance novel AND-gated bispecific therapeutics for solid tumors. The agreement includes an upfront payment of $40 million, with eligibility for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.

2026年11月14-20日,全球医药市场共签署了25项资产授权和合作协议。中国市场共达成6项交易,包括5项出海交易和1项国内交易。

中国市场,本周最大的交易是星锐医药与Pfizer就三款处于IND申报前阶段、用于治疗自身免疫性疾病的 in vivo CAR-T项目达成海外独家许可协议,首付款3.3亿美元,总金额可达26亿美元。

中国以外市场,本周共签署了19项资产授权和合作协议。最大的交易是DISCO Pharmaceuticals与AbbVie达成战略合作和许可协议,以发现和开发新的用于治疗实体瘤的AND门控双特异性疗法,首付款4000万美元,期权、开发和其他里程碑付款可达25亿美元,以及全球净销售额的分层特许权使用费。

2. Licensing Deals

China Licensing and Cooperation Deals November 2026
Deal Type Licensor Licensee Assets Disease Stage Total amount
($ million)
Upfront
($ million)
Deal Territory
China
OL
Starna Therapeutics
星锐医药
Pfizer Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology; another compound; CAR-T program 3; CAR-T program 2; STR-P006 Autoimmune Disease Pre-Clinical 2,630 330 United States; Europe; Japan; Chinese Mainland; Hong Kong, Macao and Taiwan; Global
China
OL
InnoGen
银诺医药
Arcera efsubaglutide alfa Metabolic Dysfunction-Associated Steatohepatitis (MASH); Polycystic Ovary Syndrome (PCOS); Overweight; Type 2 Diabetes; Obstructive Sleep Apnea (OSA); Diabetes; Obesity Approved 1,000 15 Other
China
OL
Longuide
厚存纳米
Undisclosed LNP technology platform Undisclosed Undisclosed Undisclosed Undisclosed Global
China
OL
Betta Pharmaceuticals
贝达药业
Mankind Pharma ensartinib Hematology; Rare Diseases; Oncology; Rare Diseases Approved Undisclosed Undisclosed Other
China
OL
Delonix Bioworks
羽冠生物
A*STAR OMV-based Klebsiella pneumoniae vaccine Klebsiella Infection Pre-Clinical Undisclosed Undisclosed Global
China
Domestic
Ditu Zhiyuan
迪途智源
Hanx Biopharmaceutical
翰思艾泰
Research Collaboration on the Meritudio BioAI Platform Oncology Undisclosed Undisclosed Undisclosed Global

2a. China Section

3. M&A Deals

M&A Deals November 2026
Status Acquiree Acquiror Acquisition Type Item Total amount
($ million)
Upfront
($ million)
Proposed Ollin Biosciences Johnson & Johnson Full Acquisition IBI324 3,325 2,200
Proposed Calytrix Bio Eli Lilly Full Acquisition biparatopic antibody 1,500 Undisclosed
Proposed Mayne Pharma Richter Group Full Acquisition estetrol+drospirenone 390 Undisclosed
Proposed Aytu BioPharma Rosemont Full Acquisition gepirone Undisclosed Undisclosed

4. Top Deals of 2026

Top China Out-Licensing and Cooperation Deals 2026
Date Licensor Licensee Field Stage Total amount
($ million)
Upfront
($ million)
2026-10-22 Peptidstar Therapeutics
瀚辰星泰
Gilead Sciences Gastroenterology; Immunology; Dermatology Phase I Undisclosed 1,275
2026-01-30 CSPC Pharma
石药集团
AstraZeneca Endocrine & Metabolic IND; Pre-Clinical 18,500 1,200
2026-05-29 Innovent Biologics
信达生物
Pfizer Oncology Pre-Clinical 10,500 650
2026-01-13 RemeGen
荣昌生物
Abbvie Rare Disease; Oncology Phase II 5,600 650
2026-05-12 Hengrui Pharmaceuticals
恒瑞医药
Bristol-Myers Squibb Haematology; Oncology Pre-Clinical 15,200 600
2026-07-14 Dizal Pharma
迪哲医药
AstraZeneca Haematology; Oncology; Rare Diseases Approved 1,500 600
2026-10-02 Abogen Biosciences
艾博生物
Novartis Undisclosed Undisclosed 7,775 575
2026-10-19 Hansoh Pharmaceutical
豪森药业
Roche Undisclosed Pre-Clinical 15,510 400
2026-09-28 SciBrunch Therapeutics
思璞锐
Merck & Co. Oncology Pre-Clinical 2,130 400
2026-11-04 Sino Biopharmaceutical
中国生物制药
Boehringer Ingelheim Undisclosed Pre-Clinical 7,000 358
Top China Domestic Licensing and Cooperation Deals 2026
Date Licensor Licensee Field Stage Total amount
($ million)
Upfront
($ million)
2026-07-21 TYK medicines
同源康医药
Qilu Pharmaceutical
齐鲁制药
Oncology Filed 384 42
2026-05-29 Genrix Bio
智翔金泰
YaoPharma
药友制药
Hematology; Rare Diseases; Immunology; Dermatology; Oncology Filed 253 42
2026-03-23 Corxel Pharmaceuticals
箕星药业
Everest Medicines
云顶新耀
Cardiovascular Approved 50 30
2026-02-05 Micot Technology
麦科奥特
Everest Medicines
云顶新耀
Genitourinary; Endocrine & Metabolic Phase III 172.48 27.82
2026-01-17 Raynovent
众生药业
Qilu Pharmaceutical
齐鲁制药
Gastroenterology; Respiratory; Endocrine & Metabolic Phase III 139.10 27.82
2026-04-28 Huahui Health
华辉安健
BeOne Medicines
百济神州
Oncology Pre-Clinical 2,024 20
2026-01-12 Wan Bang De
万邦德
Hisoar Pharmaceutical
海翔药业
Neurology; Rare Disease Pre-Clinical 20.87 16.69
2026-01-06 Accendatech
尚德药缘
Yifan Pharmaceutical
亿帆医药
Neurology; Ophthalmology; Respiratory; Hematology; Rare Disease; Immunology; Oncology Phase III 20.87 13.91
2026-02-04 Akeso Biopharma; Kangrong Dongfang
康方生物
Jumpcan Pharmaceutical
济川药业
Rare Disease; Cardiovascular Approved 12.52 11.13
2026-01-20 Insilico Medicine
英矽智能
Hengtai Biotechnology
衡泰生物
Neurology Pre-Clinical 66 10
Top Global Licensing and Cooperation Deals 2026
Date Licensor Licensee Field Stage Total amount
($ million)
Upfront
($ million)
2026-03-20 Synnovation Therapeutics Novartis Oncology Phase I/II 3,000 2,000
2026-06-01 Edgewise Therapeutics Servier Musculoskeletal; Rare Diseases Phase II 2,650 1,550
2026-10-01 Regeneron Sanofi Immunology Phase I 8,000 1,000
2026-06-08 Nurix Therapeutics Roche Haematology; Rare Diseases; Immunology; Oncology Phase III 2,300 700
2026-03-19 Corium Therapeutics Collegium Pharmaceutical Psychiatry Approved 785 650
2026-08-26 Biohaven SK Biopharmaceuticals Neurology Phase II/III 795 400
2026-10-04 Alentis Therapeutics CSL Respiratory; Gastroenterology; Immunology; Rare Diseases; Oncology; Genitourinary Phase II 1,555 355
2026-07-29 Sail Biomedicines Johnson & Johnson Immunology Pre-Clinical 925 320
2026-03-09 GSK Alfasigma Gastroenterology; Rare Disease; Dermatology; Endocrine & Metabolic Filed 690 300
2026-02-23 Vir Biotechnology Astellas Pharma Oncology Phase I/II 1,705 240

5. 2021-2025 China Innovative Drug Licensing Transactions

About YAFO Capital

YAFO Capital is a global boutique investment and BD advisory firm with professional teams across China, the U.S., Europe, and Southeast Asia. Our expertise spans four core business segments: transaction advisory and consulting, NewCo incubation, investment management, and partnering forums. Over the past 12 years, YAFO has built a strong track record, closing dozens of business development transactions with leading global pharmaceutical and biotech companies. For more information, please visit www.yafocapital.com.

关于雅法资本
雅法致力于生物医药项目的跨境及国内授权交易、成立NewCo和并购交易。基于雅法在全球广泛的人脉与资源网络,在过去十二年成功推进了大量的海外项目进入中国市场并协助诸多中国产品完成海外授权。雅法拥有经验丰富的全球交易团队,覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人背景多元化,包括华尔街资深投行交易经验及跨国药企经历,为客户交易提供全方位的强力支持。